UY24430A1 - Procedimiento para preparar vacuna contra tumores - Google Patents

Procedimiento para preparar vacuna contra tumores

Info

Publication number
UY24430A1
UY24430A1 UY24430A UY24430A UY24430A1 UY 24430 A1 UY24430 A1 UY 24430A1 UY 24430 A UY24430 A UY 24430A UY 24430 A UY24430 A UY 24430A UY 24430 A1 UY24430 A1 UY 24430A1
Authority
UY
Uruguay
Prior art keywords
patient
peptides
tumor cells
cells
tumor
Prior art date
Application number
UY24430A
Other languages
English (en)
Inventor
Walter Schmidt
Max Birnstiel
Tamas Schweighoffer
Peter Steinlein
Michael Buschle
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY24430A1 publication Critical patent/UY24430A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un procedimiento para la preparación de una vacuna contra tumores que contiene células tumorales, para su administración a un paciente. La misma se caracteriza porque las células tumorales, que por sí misma, presentan en el contexto de HLA péptidos derivados de antígenos de tumores y de las que al menos una parte expresa por lo menos un haplotipo MCH-I (MCH: complejo de histocompatibilidad principal) del paciente, se tratan con uno o varios péptido varios péptidos, que: a) funcionan como ligandos para el haplotipo MHC-I que es común al paciente y a las células tumorales de la vacuna, y son diferentes de péptidos que se derivan de proteínas que son expresadas por células del paciente o, que b) funcionan como ligandos para el haplotipo MHC-I que es común al del paciente y al de las células tumorales de la vacuna, y se derivan de antígenos tumorales que son expresados por células del paciente, incubando las células tumorales con uno o varios péptidos a) y/o b) un tiempo y en una cantidad, en presencia de un policatión orgánico hasta que los péptidos estén fijados a las células tumorales de modo que, en el contexto con las células tumorales del sistema inmune del paciente, son reconocidos como extrañas y desencadenan una respuesta inmune celular. Como policatión se emplea polilisina. Dicho policatión se emplea en forma parcialmente conjugada y está conjugado con transferrina. Se caracteriza también porque las células se tratan además en presencia de ADN (un plásmido).
UY24430A 1995-11-23 1997-01-03 Procedimiento para preparar vacuna contra tumores UY24430A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung
UY24367A UY24367A1 (es) 1995-11-23 1996-11-19 Vacunas contra tumores y procedimiento para su produccion

Publications (1)

Publication Number Publication Date
UY24430A1 true UY24430A1 (es) 1997-07-01

Family

ID=26020603

Family Applications (2)

Application Number Title Priority Date Filing Date
UY24367A UY24367A1 (es) 1995-11-23 1996-11-19 Vacunas contra tumores y procedimiento para su produccion
UY24430A UY24430A1 (es) 1995-11-23 1997-01-03 Procedimiento para preparar vacuna contra tumores

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY24367A UY24367A1 (es) 1995-11-23 1996-11-19 Vacunas contra tumores y procedimiento para su produccion

Country Status (24)

Country Link
US (1) US20020085997A1 (es)
EP (1) EP0866851A1 (es)
JP (1) JP2000502052A (es)
KR (1) KR19990067653A (es)
CN (1) CN1202931A (es)
AR (1) AR004341A1 (es)
AU (1) AU720131B2 (es)
BG (1) BG62999B1 (es)
BR (1) BR9611466A (es)
CA (1) CA2238176A1 (es)
CO (1) CO4520254A1 (es)
CZ (1) CZ158998A3 (es)
EE (1) EE03778B1 (es)
HU (1) HUP0000318A3 (es)
NO (1) NO982329D0 (es)
NZ (1) NZ322910A (es)
PL (1) PL188537B1 (es)
RO (1) RO115275B1 (es)
RU (1) RU2206329C2 (es)
SK (1) SK66998A3 (es)
TR (1) TR199800912T2 (es)
TW (1) TW514530B (es)
UY (2) UY24367A1 (es)
WO (1) WO1997019169A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6187307B1 (en) * 1997-01-31 2001-02-13 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
DK0904786T3 (da) * 1997-08-22 2005-03-21 Science Park Raf S P A Tumorvaccination under anvendelse af autologe eller HLA-relaterede antigenpræsenterende celler (APC) transduceret med et tumorantigen og et fremmed antigen, som kan fremkalde en immunreaktion
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
US20060035291A1 (en) * 2001-09-18 2006-02-16 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
ATE475430T1 (de) * 2003-08-25 2010-08-15 Univax Llc Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
EP1871166A4 (en) 2005-03-29 2008-11-12 Univ Illinois VACCINES AGAINST CANCER AND THERAPEUTIC METHODS
DK1806359T3 (da) * 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8765148B2 (en) 2010-02-19 2014-07-01 Valneva Austria Gmbh 1C31 nanoparticles
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
JP6710004B2 (ja) 2016-03-15 2020-06-17 Repertoire Genesis株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
EP4304615A1 (en) * 2021-03-12 2024-01-17 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0569678A3 (en) * 1992-03-13 1994-10-26 Yeda Res & Dev Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis.

Also Published As

Publication number Publication date
CO4520254A1 (es) 1997-10-15
UY24367A1 (es) 2000-10-31
HUP0000318A2 (hu) 2000-06-28
BR9611466A (pt) 1999-05-18
KR19990067653A (ko) 1999-08-25
SK66998A3 (en) 1998-12-02
NO982329D0 (no) 1998-05-22
CN1202931A (zh) 1998-12-23
CZ158998A3 (cs) 1999-06-16
BG62999B1 (bg) 2001-01-31
AU7694796A (en) 1997-06-11
US20020085997A1 (en) 2002-07-04
NZ322910A (en) 2000-05-26
EP0866851A1 (de) 1998-09-30
PL188537B1 (pl) 2005-02-28
TW514530B (en) 2002-12-21
AU720131B2 (en) 2000-05-25
AR004341A1 (es) 1998-11-04
CA2238176A1 (en) 1997-05-29
JP2000502052A (ja) 2000-02-22
TR199800912T2 (xx) 1998-08-21
HUP0000318A3 (en) 2002-02-28
EE9800161A (et) 1998-12-15
BG102439A (en) 1999-01-29
RO115275B1 (ro) 1999-12-30
RU2206329C2 (ru) 2003-06-20
EE03778B1 (et) 2002-06-17
PL326756A1 (en) 1998-10-26
WO1997019169A1 (de) 1997-05-29

Similar Documents

Publication Publication Date Title
UY24430A1 (es) Procedimiento para preparar vacuna contra tumores
CY1115749T1 (el) Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια
US7528224B1 (en) Peptide for triggering an immune reaction against tumor cells
JPH09503902A (ja) 組み換えウイルス免疫治療
CN101824400B (zh) 一种放大增殖抗原特异性t细胞的方法
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
de Visser et al. Tracing and characterization of the low‐avidity self‐specific T cell repertoire
Bauer et al. Polypeptides of avian RNA tumor viruses: II. Serological characterization
Saalmüller et al. Characteristics of porcine T lymphocytes and T-cell lines
RU2017127024A (ru) Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н
CN101512000B (zh) 生产寡肽的方法
EA012520B1 (ru) Способ получения цитотоксических лимфоцитов
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
CN102159240B (zh) 基于狂犬病毒的重组免疫避孕组合物及其使用方法
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
RU2660566C2 (ru) Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген
Li et al. Immunogenicity assessment of rift valley fever virus virus-like particles in BALB/c mice
SE9903534D0 (sv) Vaccin
Mohd-Lila et al. The application of naked DNA plasmid (DrZP3) and recombinant adenovirus (Ad-rZP3) in rat animal model to determine comparative efficacy of ZP3-Immunocontraceptive vaccines
HU227667B1 (en) Novel expression vectors and uses thereof
Clydesdale et al. Contraception in mice immunized with recombinant zona pellucida subunit 3 proteins correlates with Th2 responses and the levels of interleukin 4 expressed by CD4+ cells
Kast et al. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes
Sjaastad et al. Reduced T Cell Priming in Microbially Experienced “Dirty” Mice Results from Limited IL-27 Production by XCR1+ Dendritic Cells
Damjanov et al. Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host
Barra et al. Isolation of polyoma virus-induced surface antigens in hamster cells: potassium chloride solubilization and differential precipitation

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170103